Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN F RICO

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1790912665
CMS profile
471485
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$989.36

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $854.39 3
Food and Beverage $134.97 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $989.36 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN F RICO

NPI 1790912665 · CMS profile ID 471485

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790912665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN F RICO, NPI 1790912665, CMS profile ID 471485. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790912665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUAN F RICO, NPI 1790912665, CMS profile ID 471485. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790912665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUAN F RICO, NPI 1790912665, CMS profile ID 471485, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790912665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $989.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $297.3907/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659857787 CMS
Novartis Pharmaceuticals Corporation $223.0007/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659857789 CMS
Novartis Pharmaceuticals Corporation $134.9707/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659857791 CMS
Novartis Pharmaceuticals Corporation $334.0007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659857785 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $989.36 4
PY2022 $122.12 1
PY2023 $377.28 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $15,620.00 12
PY2023 Principal investigator $62,089.00 29
PY2022 Principal investigator $42,961.44 17
PY2021 Principal investigator $70,975.10 83
PY2020 Principal investigator $67,972.02 22
PY2019 Principal investigator $228,077.73 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Global Blood Therapeutics, Inc. $255.00 12/15/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914608431
Principal investigator 1 Global Blood Therapeutics, Inc. $650.00 11/25/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914608425
Principal investigator 1 Global Blood Therapeutics, Inc. $4,135.00 11/22/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608421
Principal investigator 1 Global Blood Therapeutics, Inc. $13,335.00 10/20/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914608415
Principal investigator 1 Global Blood Therapeutics, Inc. $300.00 10/18/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608409
Principal investigator 1 Global Blood Therapeutics, Inc. $4,135.00 10/11/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
Open-label Ext Study to Eval the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Primary objective of this study is to evaluate the long-term safety of every 12-wk dosing of inclacumab in participants with sickle cell disease (SCD)whohave completed a prior inclacumab clinical trial.Additional objectives areto evaluate the incidence of vaso-occlusive crises (VOCs), hospitalizations, missed work/schooldays No dispute reported 06/30/2026 914608403
Principal investigator 1 Daiichi Sankyo Inc. $375.00 08/15/2022 Non-covered Recipient Entity
University Of South Florida Diabetes Center
DU176B-D-U312 No dispute reported 06/30/2026 935024829
Principal investigator 1 Daiichi Sankyo Inc. $600.00 08/15/2022 Non-covered Recipient Entity
University Of South Florida Diabetes Center
DU176B-D-U312 No dispute reported 06/30/2026 935024843
Principal investigator 1 Daiichi Sankyo Inc. $500.00 08/15/2022 Non-covered Recipient Entity
University Of South Florida Diabetes Center
DU176B-D-U312 No dispute reported 06/30/2026 935024917
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 08/15/2022 Non-covered Recipient Entity
University Of South Florida Diabetes Center
DU176B-D-U312 No dispute reported 06/30/2026 935024923
Principal investigator 1 Daiichi Sankyo Inc. $14.60 08/08/2022 Non-covered Recipient Entity
Usf Health
DU176b-D-U312 No dispute reported 06/30/2026 935024825
Principal investigator 1 Global Blood Therapeutics, Inc. $500.00 08/02/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608465
Principal investigator 1 Global Blood Therapeutics, Inc. $3,740.00 04/14/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608455
Principal investigator 1 Global Blood Therapeutics, Inc. $2,500.00 04/01/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608437
Principal investigator 1 Global Blood Therapeutics, Inc. $3,750.00 04/01/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608443
Principal investigator 1 Global Blood Therapeutics, Inc. $2,500.00 04/01/2022 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises No dispute reported 06/30/2026 914608449
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,171.84 01/27/2022 Non-covered Recipient Entity
USF HEALTH
A PHASE II MULTICENTER STUDY TO CONFIRM PK PD OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN ADULT SICKLE CELL DISEASE PATIENTS WITH HISTORY OF VOC No dispute reported 06/30/2026 909425155